Phase 1b Study of Olaparib and Estradiol in Advanced ER+ Breast Cancer (PHOEBE)
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:
• Post-menopausal women with ER+/HER2- breast cancer.
• Metastatic or locoregional recurrence not amenable to treatment with curative intent.
• Received ≥1 prior line of endocrine-based therapy in the advanced/metastatic setting.
Locations
United States
New Hampshire
Dartmouth Cancer Center
RECRUITING
Lebanon
Contact Information
Primary
Research Nurse
Cancer.Research.Nurse@dartmouth.edu
1-800-639-6918
Time Frame
Start Date: 2024-07-15
Estimated Completion Date: 2028-12
Participants
Target number of participants: 6
Treatments
Experimental: Treatment Arm
Participants receive 2 cycles of olaparib in combination with 17b-estradiol and then continue to be treated with single-agent 17b-estradiol until disease progression.
Related Therapeutic Areas
Sponsors
Collaborators: Dartmouth-Hitchcock Medical Center
Leads: Mary D Chamberlin